New imaging scan to detect heart muscle changes in ARVC

Plain-English translation of NCT07563660 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated August 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing whether a new imaging scan called 68Ga-DOTA-SA-FAPI PET/CT can help doctors better understand and diagnose arrhythmogenic right ventricular cardiomyopathy (ARVC), a genetic condition where heart muscle gradually gets replaced by scar tissue. The scan is designed to detect active changes in the heart that standard imaging tests may miss, especially early in the disease. This could help doctors identify who is at highest risk for dangerous heart rhythms or heart failure.

Current imaging tests like echocardiograms and cardiac MRI show the structure and function of the heart, but they may not detect the early scar tissue formation that causes electrical problems in ARVC. This new imaging scan specifically looks for active scar formation, which could help doctors catch and treat the disease earlier before serious complications develop.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with ARVC according to established medical criteria
you are currently being followed by doctors at the study center
you are able to understand the study and give written consent

You likely don't qualify if…

you have a history of cancer
you have severe kidney or liver disease
you are pregnant or breastfeeding
you have previously had this specific FAPI PET/CT imaging scan
you are unable or unwilling to provide written consent

What participation looks like

If you join this study, you will undergo the new imaging scan (68Ga-DOTA-SA-FAPI PET/CT), along with standard heart tests including an EKG, echocardiogram, and review of any previous heart MRI scans you've had. Researchers will also do a clinical evaluation and basic blood work. After your initial visit, you'll be followed for 6 months with check-ins to see how you're doing and to gather information about your heart health.

AI-generated summary from trial data · Aug 9, 2026 · Not medical advice

Trial locations(1 site)

Turkey (Türkiye)

Istanbul University-Cerrahpasa Institute of Cardiology, Istanbul, Fatih

Key details

Sponsor

Istanbul University - Cerrahpasa

Enrollment target

~15 participants

Started

April 2025

Primary completion

August 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated on clinicaltrials.gov in May 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Sukru Arslan, MD, Associate Professor

Istanbul University - Cerrahpasa

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov